Cereno scientific therapeutic areas
WebCereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease... WebApr 13, 2024 · Born 1977. Jonas Faijerson Säljö has a research background in the stroke area with wide-ranging experience in the commercialization of medical innovations. Faijerson Säljö has significant expertise in intellectual property and business development experience from a large number of companies in the life science area. He is currently …
Cereno scientific therapeutic areas
Did you know?
WebDec 10, 2024 · Cereno Scientifics aim is to form a platform of drug candidates that affects the field of epigenetic modulation through "HDAC inhibition" (Histone DeACetylase inhibition). The company's first program, CS1, is a phase II dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. WebFeb 28, 2024 · Cereno Scientific AB (publ), clinical stage biotech company, develops therapeutics to treat cardiovascular and rare diseases through epigenetic modulation worldwide. Its lead drug candidate is CS1, a product candidate that is in Phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension and thrombotic indications.
WebIn connection to the directed issue that was completed in September 2024 a total of 34,519,281 warrants of series TO2 was issued. Each warrant of series TO2 will give the holder the right to subscribe for one new share of series B in Cereno during the period from 14 September 2024 until and including 28 September 2024 to a subscription price ... WebAug 2, 2024 · Björn Dahlöf Cereno Scientific Björn Dahlöf 31 Aug 2024 Born 1953. Björn Dahlöf has extensive experience in cardiovascular research, pharmacology, drug development, and clinical trials (all phases) and has lectured in these areas internationally.
WebNov 16, 2024 · Cereno Insights Series: CS1 -PAH Clinical Trial Design with Sörensen, Dahlöf & Adamson Presentation 24 Nov 2024 Infocus interview and presentation at Redeye Life Science Day Interview 16 Nov 2024 CEO interview in conjunction with the Q3 report 2024 (Swedish) Presentation 14 Sep 2024 Company presentation and Q&A at BioStock … WebFeb 4, 2024 · Experimental: CS1 1920 mg dose group. 1920 mg of CS1, twice daily administration with 1/3 of the dose in the morning and 2/3 in the evening. Drug: CS1 …
WebCereno Scientific is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company’s lead program, CS1, is a phase II dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation.
WebAug 2, 2024 · Therapeutic focus Corporate governance Newsroom Press releases Events & presentations Event calendar Investors Investment story Share information Share issues Financial reports Financial calendar … linear bonus protettoWebCereno Scientific AB develops drugs that normalize the body's own defense system against blood clots for the treatment of complications in cardiovascular diseases. Lists Featuring This Company European Union (EU) Health Care Companies (Top 10K) 9,796 Number of Organizations • $64.1B Total Funding Amount • 9,006 Number of Investors … hot pot torinoWebAug 23, 2024 · Cereno Scientific is planning to begin a Phase 2 clinical trial of CS1 — the company’s lead therapy candidate for pulmonary arterial hypertension (PAH) — this September, following clearance from the U.S. Food and Drug Administration (FDA). hot pot townWebAt a glance Originator Cereno Scientific Class Anti-ischaemics; Antiarrhythmics; Antiepileptic drugs; Antimigraines; Antithrombotics; Cardiovascular therapies; Nootropics; Pentanoic acids; Small molecules; Vascular disorder therapies hot pot towsonWebBIO-Europe 2024 Cereno Scientific will attend BIO-Europe 2024. Contact Sten R. Sörensen on +46 (0) 733 74 03 74 or [email protected] to schedule... Read more about the event here linear book case lightingWebSep 9, 2024 · Cereno Scientific (XSAT: CRNO B) today announced that a patent has been allowed in the second patent family for the preclinical Prostacyclin Receptor Agonist Program, which includes drug candidate CS585. ... granted a patent in the US in its first patent family titled “Hydroxyeicosatrienoic acid compounds and their use as therapeutic … linear bookWebJun 14, 2024 · Cereno Scientific is a biotech company focusing on developing innovative treatments for patients affected by common and rare cardiovascular diseases. Cardiovascular disease is the number 1 cause of death globally, killing nearly twice as many people as cancer. hot pot towson md